Logo image of RCAT

RED CAT HOLDINGS INC (RCAT) Stock Fundamental Analysis

NASDAQ:RCAT - Nasdaq - US75644T1007 - Common Stock - Currency: USD

8.57  +1.79 (+26.4%)

After market: 8.54 -0.03 (-0.35%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RCAT. RCAT was compared to 125 industry peers in the Electronic Equipment, Instruments & Components industry. RCAT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RCAT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RCAT has reported negative net income.
In the past year RCAT has reported a negative cash flow from operations.
In the past 5 years RCAT always reported negative net income.
RCAT had a negative operating cash flow in each of the past 5 years.
RCAT Yearly Net Income VS EBIT VS OCF VS FCFRCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

RCAT has a Return On Assets of -132.42%. This is amonst the worse of the industry: RCAT underperforms 92.80% of its industry peers.
RCAT has a Return On Equity of -250.32%. This is amonst the worse of the industry: RCAT underperforms 94.40% of its industry peers.
Industry RankSector Rank
ROA -132.42%
ROE -250.32%
ROIC N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
RCAT Yearly ROA, ROE, ROICRCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

RCAT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCAT Yearly Profit, Operating, Gross MarginsRCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

More info and screens

3

2. Health

2.1 Basic Checks

RCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
RCAT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RCAT has more shares outstanding
RCAT has a better debt/assets ratio than last year.
RCAT Yearly Shares OutstandingRCAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RCAT Yearly Total Debt VS Total AssetsRCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

RCAT has an Altman-Z score of 10.13. This indicates that RCAT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.13, RCAT belongs to the top of the industry, outperforming 88.80% of the companies in the same industry.
A Debt/Equity ratio of 0.44 indicates that RCAT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.44, RCAT is not doing good in the industry: 65.60% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 10.13
ROIC/WACCN/A
WACC9.45%
RCAT Yearly LT Debt VS Equity VS FCFRCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RCAT has a Current Ratio of 1.43. This is a normal value and indicates that RCAT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of RCAT (1.43) is worse than 79.20% of its industry peers.
RCAT has a Quick Ratio of 1.43. This is a bad value and indicates that RCAT is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of RCAT (0.57) is worse than 93.60% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.57
RCAT Yearly Current Assets VS Current LiabilitesRCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

RCAT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.62%.
The Revenue for RCAT has decreased by -64.52% in the past year. This is quite bad
RCAT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 176.68% yearly.
EPS 1Y (TTM)-9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)-64.52%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-60.96%

3.2 Future

Based on estimates for the next years, RCAT will show a very strong growth in Earnings Per Share. The EPS will grow by 39.49% on average per year.
Based on estimates for the next years, RCAT will show a very strong growth in Revenue. The Revenue will grow by 123.37% on average per year.
EPS Next Y-0.3%
EPS Next 2Y49.88%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue Next Year341.59%
Revenue Next 2Y188.86%
Revenue Next 3Y123.37%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RCAT Yearly Revenue VS EstimatesRCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
RCAT Yearly EPS VS EstimatesRCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCAT. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 86.91, the valuation of RCAT can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RCAT is on the same level as its industry peers.
RCAT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.76.
Industry RankSector Rank
PE N/A
Fwd PE 86.91
RCAT Price Earnings VS Forward Price EarningsRCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCAT Per share dataRCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

RCAT's earnings are expected to grow with 39.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.88%
EPS Next 3Y39.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCAT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RED CAT HOLDINGS INC

NASDAQ:RCAT (7/11/2025, 8:00:02 PM)

After market: 8.54 -0.03 (-0.35%)

8.57

+1.79 (+26.4%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners19.83%
Inst Owner Change0%
Ins Owners14.89%
Ins Owner Change0%
Market Cap779.18M
Analysts84.44
Price Target13.6 (58.69%)
Short Float %14.8%
Short Ratio1.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-72.94%
Min EPS beat(2)-152.1%
Max EPS beat(2)6.22%
EPS beat(4)1
Avg EPS beat(4)-91.86%
Min EPS beat(4)-152.1%
Max EPS beat(4)6.22%
EPS beat(8)2
Avg EPS beat(8)-82.2%
EPS beat(12)3
Avg EPS beat(12)-129.91%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-56.98%
Min Revenue beat(2)-80.52%
Max Revenue beat(2)-33.43%
Revenue beat(4)0
Avg Revenue beat(4)-30.49%
Min Revenue beat(4)-80.52%
Max Revenue beat(4)-1.15%
Revenue beat(8)2
Avg Revenue beat(8)-19.08%
Revenue beat(12)3
Avg Revenue beat(12)-27.24%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.76%
PT rev (3m)-4.76%
EPS NQ rev (1m)72.22%
EPS NQ rev (3m)72.22%
EPS NY rev (1m)-31.11%
EPS NY rev (3m)-67.37%
Revenue NQ rev (1m)299.45%
Revenue NQ rev (3m)299.45%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)114.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 86.91
P/S 148.75
P/FCF N/A
P/OCF N/A
P/B 28.83
P/tB 1248.29
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)0.1
Fwd EY1.15%
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.06
BVpS0.3
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -132.42%
ROE -250.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.5%
Cap/Sales 3.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 0.57
Altman-Z 10.13
F-Score1
WACC9.45%
ROIC/WACCN/A
Cap/Depr(3y)137.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y-0.3%
EPS Next 2Y49.88%
EPS Next 3Y39.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-64.52%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-60.96%
Revenue Next Year341.59%
Revenue Next 2Y188.86%
Revenue Next 3Y123.37%
Revenue Next 5YN/A
EBIT growth 1Y-59.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.73%
EBIT Next 3Y56.58%
EBIT Next 5YN/A
FCF growth 1Y-63.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.9%
OCF growth 3YN/A
OCF growth 5YN/A